Topic: Novel Approaches for HCC

Download All Articles

A special issue of Hepatoma Research  (Print ISSN:2394-5079; Online ISSN:2454-2520).

Deadline for manuscript submissions: 30 Jun 2018

Share This Special Issue

Guest Editor(s)

  • Lynn G. Feun, MD
    Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.

    E-mail

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.editorialmanager.com/hres/default.aspx
Submission Deadline: 30 Jun 2018
Contacts: Siqi Li, Assistant Editor, editor001@hrjournal.net

Published Articles Download All Articles
  • The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

    Walid S. Ayoub , Francis Dailey , Paul Martin , Patricia D. Jones
    Worldwide, hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality. In men, it is the fifth most common cancer and seventh most common in women; HCC is the second highest cause of cancer-related death worldwide. It is less prevalent in the USA and Northern Europe and more prevalent in Eastern and South-Eastern Asia. Over 700,000 cases are diagnosed each year - half of which occur in China - and result in roughly the same number of deaths per year. HCC significantly impairs quality of life and is associated with great costs to society. It is estimated that half of... Read more
    Hepatoma Res 2017;3:302-8. | doi:10.20517/2394-5079.2016.44
    Published on: 20 Dec 2017  | Viewed:316  | Downloaded:22
    +HTML| PDF
  • Immunotherapy for hepatocellular carcinoma: the force awakens in HCC?

    Lynn G. Feun , Ying-Ying Li , Medhi Wangpaichitr , Chun-Jing Wu , Niramol Savaraj
    Systemic therapy for hepatocellular carcinoma (HCC) has been disappointing. The only drug approved by Food and Drug Administration recently has been sorafenib. Sorafenib has modest benefits with a low response rate and an improvement in time to progression of only 2-3 months. Multiple randomized trials, which compare the new agent to sorafenib as either first line or second line therapy, have been negative, showing no improved clinical benefit. Recently, in a large phase III randomized trial, regorafenib has shown superiority to placebo as a second line treatment for HCC. However, this drug... Read more
    Hepatoma Res 2017;3:43-51. | doi:10.20517/2394-5079.2016.45
    Published on: 22 Mar 2017  | Viewed:3088  | Downloaded:700
    +HTML| PDF
Hepatoma Research Print ISSN: 2394-5079; Online ISSN: 2454-2520
Quick Links
  • OAE Publishing Inc. (OAE) is an online open-access publisher specializing in the publication of biomedical peer-reviewed journals...

  • Contact us
  • Leave feedback
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.